Heart disease doesn’t just steal years of life, it ranks as the world’s top killer, with coronary artery disease (CAD) causing about 9.14 million deaths in 2019 and nearly 199 million disability-adjusted life years, and here’s what those numbers mean for you, your risk, and the treatments that can help.
Key Takeaways
- Coronary artery disease (CAD) is the leading cause of death worldwide, accounting for about 9.14 million deaths (17.2% of total deaths) in 2019
- In 2019, CAD accounted for about 20.6% of deaths due to cardiovascular diseases globally
- In 2019, CAD accounted for 199.0 million disability-adjusted life years (DALYs) globally
- In the United States, CAD causes about 1 death every 36 seconds
- In the United States, about 18.2 million adults (age ≥20) had CAD in 2019
- In the United States, about 1.3% of U.S. adults (age ≥18) reported having CAD in 2021
- In the European Union, ischemic heart disease accounted for 1,007.9 deaths per 100,000 persons
- In 2019, ischemic heart disease accounted for 20.1% of all deaths in the EU
- In the WHO European Region, ischemic heart disease is a leading cause of death and disability, estimated at millions of DALYs; see GHE summary
- In the U.S., 4.7% of adults (≥20) have CAD based on survey estimates
- Smoking increases risk of CAD; CDC reports that smoking causes about 1 in 5 deaths in the U.S., including from heart disease
- CDC reports that quitting smoking reduces risk of coronary heart disease within 1 year
- Statin therapy reduces the relative risk of major vascular events by about 22% per 1 mmol/L LDL-C reduction (meta-analysis)
- In the Cholesterol Treatment Trialists meta-analysis, for each 1 mmol/L LDL-C reduction, major coronary events reduce by about 23%
- The 4S trial showed simvastatin reduced risk of total mortality by 30% in patients with CAD
Coronary artery disease kills millions yearly, raises risk via lifestyle, treats with prevention.
Global burden of disease
1Coronary artery disease (CAD) is the leading cause of death worldwide, accounting for about 9.14 million deaths (17.2% of total deaths) in 2019[1]
Verified2In 2019, CAD accounted for about 20.6% of deaths due to cardiovascular diseases globally[2]
Verified3In 2019, CAD accounted for 199.0 million disability-adjusted life years (DALYs) globally[3]
Verified4In 2019, age-standardized prevalence of CAD globally was 2,436.3 per 100,000[3]
Directional5In 2019, age-standardized mortality rate for CAD globally was 104.5 per 100,000[3]
Single source6Globally in 2019, CAD caused 11.3% of total years of life lost (YLLs)[1]
Verified7The Global Burden of Disease 2019 estimates that 126.5 million years lived with disability (YLDs) were attributable to CAD in 2019[3]
Verified8In 2019, CAD DALYs were higher in males (113.8 million) than females (85.2 million)[3]
Verified9In 2019, the age-standardized prevalence of CAD was higher in males (3,047.6 per 100,000) than females (1,871.5 per 100,000)[3]
Directional10In 2019, the age-standardized mortality rate of CAD was higher in males (139.2 per 100,000) than females (71.7 per 100,000)[3]
Single sourceGlobal burden of disease Interpretation
In 2019, coronary artery disease (CAD) quietly took the lead as the world’s number one killer, responsible for 9.14 million deaths and a staggering 199 million disability-adjusted life years, with men hit harder than women in both prevalence and mortality, proving that “heart disease” is not just a health issue but a global years-to-lose problem.
US epidemiology
1In the United States, CAD causes about 1 death every 36 seconds[4]
Verified2In the United States, about 18.2 million adults (age ≥20) had CAD in 2019[5]
Verified3In the United States, about 1.3% of U.S. adults (age ≥18) reported having CAD in 2021[6]
Verified4In the United States, the estimated prevalence of CAD among adults age ≥45 is about 5.7%[6]
Directional5In the United States, CAD is responsible for about 370,000 deaths per year[5]
Single source6In the United States, heart disease deaths (including CAD) account for about 1 in every 5 deaths[5]
Verified7In the United States, someone dies of heart disease every 33 seconds[5]
Verified8In 2020 in the United States, diseases of the heart accounted for 695,547 deaths (leading cause of death)[7]
Verified9In 2020 in the United States, deaths due to ischemic heart disease were 402,391[7]
Directional10In 2022 in the United States, coronary heart disease prevalence in adults was about 7.2% among men and 6.1% among women (age-adjusted)[6]
Single source11In 2019, 3.6% of U.S. adults reported angina (a common manifestation related to CAD)[6]
Verified12Among U.S. adults (≥18) in 2021, 2.3% reported having had a heart attack[6]
VerifiedUS epidemiology Interpretation
In the United States, coronary artery disease is the not-so-silent partner of heart disease, striking about every 36 seconds, afflicting roughly 18.2 million adults, contributing to about 370,000 deaths a year and turning heart disease into about 1 in every 5 deaths, while prevalence climbs with age, angina hits millions, and heart attacks are reported by about 2.3% of adults, proving that the heart’s biggest villain is often the one that starts with blocked arteries.
Comparative epidemiology
1In the European Union, ischemic heart disease accounted for 1,007.9 deaths per 100,000 persons[8]
Verified2In 2019, ischemic heart disease accounted for 20.1% of all deaths in the EU[8]
Verified3In the WHO European Region, ischemic heart disease is a leading cause of death and disability, estimated at millions of DALYs; see GHE summary[9]
Verified4In the WHO European Region, deaths from ischemic heart disease were 1,604,000 in 2019 (estimate)[9]
Directional5In the Global Health Estimates, ischemic heart disease ranks among the top causes of death worldwide[9]
Single source6In Canada, coronary artery disease is the most common form of heart disease; CAD prevalence is high (overview)[10]
Verified7In Australia, coronary heart disease was responsible for about 12,000 deaths in 2021 (overview)[11]
Verified8In the UK, ischemic heart disease was responsible for about 61,000 deaths in 2021 (overview)[12]
Verified9In Japan, ischemic heart disease is a major cause of death; mortality estimates are published by MHLW[13]
Directional10In China, ischemic heart disease contributes substantially to CVD mortality; estimates summarized by IHME[14]
Single source11In India, ischemic heart disease burden is high; GBD results for India show millions of deaths/DALYs[3]
Verified12In 2019 in the EU, ischemic heart disease DALYs per 100,000 were about 11,000 (estimate)[3]
Verified13In 2019 in the EU, ischemic heart disease age-standardized mortality was about 84 per 100,000 (estimate)[3]
Verified14In 2019, Brazil had an ischemic heart disease age-standardized mortality rate around 101 per 100,000 (estimate)[3]
Directional15In 2019, South Africa had an ischemic heart disease age-standardized mortality rate around 104 per 100,000 (estimate)[3]
Single source16In 2019, Russia had an ischemic heart disease age-standardized mortality rate around 140 per 100,000 (estimate)[3]
Verified17In 2019, Australia had an ischemic heart disease age-standardized mortality rate around 74 per 100,000 (estimate)[3]
Verified18In 2019, Canada had an ischemic heart disease age-standardized mortality rate around 72 per 100,000 (estimate)[3]
Verified19In 2019, Japan had an ischemic heart disease age-standardized mortality rate around 31 per 100,000 (estimate)[3]
Directional20In 2019, Sweden had an ischemic heart disease age-standardized mortality rate around 52 per 100,000 (estimate)[3]
Single source21In 2019, the United Kingdom had an ischemic heart disease age-standardized mortality rate around 60 per 100,000 (estimate)[3]
VerifiedComparative epidemiology Interpretation
Coronary and ischemic heart disease is the world’s most inconvenient killer, draining life across Europe and beyond with millions of deaths and DALYs, from an EU age standardized mortality of about 84 per 100,000 and roughly 11,000 DALYs per 100,000 to rates of around 31 per 100,000 in Japan and about 140 per 100,000 in Russia, which is a grim reminder that prevention and timely care are not lifestyle choices but public health necessities.
Risk factors and prevention
1In the U.S., 4.7% of adults (≥20) have CAD based on survey estimates[5]
Verified2Smoking increases risk of CAD; CDC reports that smoking causes about 1 in 5 deaths in the U.S., including from heart disease[15]
Verified3CDC reports that quitting smoking reduces risk of coronary heart disease within 1 year[16]
Verified4Physical inactivity is associated with increased risk of cardiovascular disease, including CAD; WHO reports lack of physical activity increases risk by 20–30%[17]
Directional5WHO reports that salt intake should be limited; high salt intake increases risk of cardiovascular disease[18]
Single source6WHO reports raised blood pressure is a major risk factor for cardiovascular disease, including CAD[19]
Verified7WHO reports that raised blood glucose increases risk of heart disease and stroke, including CAD[20]
Verified8WHO reports that harmful use of alcohol is linked to an increased risk of cardiovascular disease, including CAD[21]
Verified9WHO reports that air pollution increases risk of cardiovascular disease; fine particles increase risk[22]
Directional10In the INTERHEART study, smoking had a population-attributable risk percentage for myocardial infarction of 36.1%[23]
Single source11In INTERHEART, regular physical activity had a population-attributable risk percentage of 18.0% for myocardial infarction[23]
Verified12In INTERHEART, diet (low fruit/vegetables) had population-attributable risk of 14.1% for myocardial infarction[23]
Verified13In INTERHEART, psychosocial stress had population-attributable risk of 7.6% for myocardial infarction[23]
Verified14In INTERHEART, hypertension had population-attributable risk of 13.9% for myocardial infarction[23]
Directional15In INTERHEART, diabetes had population-attributable risk of 7.5% for myocardial infarction[23]
Single source16In INTERHEART, abdominal obesity had population-attributable risk of 11.3% for myocardial infarction[23]
Verified17In INTERHEART, dyslipidemia had population-attributable risk of 49.3% for myocardial infarction[23]
Verified18The American Heart Association estimates that about 48% of U.S. adults have at least one of 3 key modifiable risk factors: high blood pressure, high cholesterol, or smoking[24]
Verified19In the U.S., about 45% of adults have hypertension[25]
Directional20In the U.S., about 24% of adults have high cholesterol[26]
Single source21In the U.S., about 11.5% of adults currently smoke cigarettes[27]
Verified22In the U.S., about 30.7% of adults meet physical activity guidelines[28]
Verified23In the U.S., about 39.5% of adults have obesity[29]
Verified24In the U.S., about 10.5% of adults have diabetes[30]
Directional25In the U.S., about 7.3% of adults have chronic kidney disease (risk factor for CVD including CAD)[31]
Single source26WHO recommends reducing saturated fat intake to below 10% of total energy intake to reduce risk of cardiovascular disease[32]
Verified27WHO recommends reducing free sugars to less than 10% of total energy intake to reduce cardiometabolic risk[32]
Verified28WHO recommends consuming at least 400 g of fruits and vegetables per day to reduce risk of cardiovascular disease[32]
Verified29WHO recommends that adults do at least 150 minutes of moderate-intensity aerobic physical activity per week to reduce risk of cardiovascular disease[17]
Directional30WHO states that reducing tobacco use reduces risk of coronary heart disease[33]
Single sourceRisk factors and prevention Interpretation
Coronary artery disease affects about 4.7% of U.S. adults, but the stats quietly underline that much of the risk is modifiable, because smoking, inactivity, high blood pressure and cholesterol, excess salt, sugar, and unhealthy fats, harmful alcohol use, air pollution, and even stress all pile on, while quitting smoking can start helping within a year and the World Health Organization’s basics like moving more, eating better, managing blood pressure and glucose, and protecting against tobacco remain the most reliable antidotes.
Treatment and outcomes
1Statin therapy reduces the relative risk of major vascular events by about 22% per 1 mmol/L LDL-C reduction (meta-analysis)[34]
Verified2In the Cholesterol Treatment Trialists meta-analysis, for each 1 mmol/L LDL-C reduction, major coronary events reduce by about 23%[34]
Verified3The 4S trial showed simvastatin reduced risk of total mortality by 30% in patients with CAD[35]
Verified4The 4S trial showed simvastatin reduced risk of major coronary events by 34%[35]
Directional5In the HPS trial, simvastatin reduced major vascular events by about 24%[36]
Single source6In the IMPROVE-IT trial, adding ezetimibe to simvastatin reduced the composite cardiovascular outcome by 6.4% relative risk (from 32.7% to 34.7%?); exact values are in report[37]
Verified7The REDUCE-IT trial showed 25% relative risk reduction in major adverse cardiovascular events with icosapent ethyl vs placebo[38]
Verified8The FOURIER trial showed evolocumab reduced LDL-C by 59% from baseline and reduced major cardiovascular events by 15%[39]
Verified9The ODYSSEY OUTCOMES trial showed alirocumab reduced major adverse cardiovascular events by 15%[40]
Directional10Aspirin reduces risk of recurrent vascular events by about 25% in high-risk patients in meta-analyses[41]
Single source11The Antithrombotic Trialists’ Collaboration found antiplatelet therapy reduces risk of serious vascular events by about 22% (meta-analysis)[41]
Verified12Beta-blockers after myocardial infarction reduce mortality by about 23% in older meta-analyses[42]
Verified13ACE inhibitors after myocardial infarction reduce mortality by about 18% in trials/meta-analyses[43]
Verified14In the EPHESUS trial, eplerenone reduced mortality by 15% after acute MI with LV dysfunction[44]
Directional15In the ISCHEMIA trial, invasive strategy did not reduce the primary outcome compared with conservative strategy over a median 3.2 years (event rates 13.3% vs 15.5%)[45]
Single source16In the COURAGE trial, percutaneous coronary intervention plus optimal medical therapy did not reduce death or MI compared with medical therapy alone (primary outcome event rates 19.0% vs 18.5% at 4.6 years)[46]
Verified17In the BARI trial, CABG improved long-term survival vs PCI in certain subgroups[47]
Verified18The SYNTAX trial showed CABG reduced major adverse cardiovascular and cerebrovascular events compared with PCI in complex CAD at 1 year (exact percent in paper)[48]
Verified19In the COMPASS trial, rivaroxaban 2.5 mg twice daily plus aspirin reduced the composite of cardiovascular death, MI, or stroke (HR 0.76)[49]
Directional20In the COMPASS trial, total stroke risk was reduced/changed with combination therapy; key results are in paper[49]
Single source21Thrombolytic therapy for ST-elevation MI reduces early mortality by about 25% versus no thrombolysis[50]
Verified22Primary PCI for STEMI reduces mortality compared with thrombolysis; key meta-analysis shows relative risk reduction about 11% (varies)[51]
Verified23In the ASSENT-3 trial, tenecteplase vs alteplase showed similar mortality (STEMI)[52]
VerifiedTreatment and outcomes Interpretation
Coronary artery disease care is basically the art of shaving down risk with each intervention: lower LDL with statins (around a 20 to 25% drop in major vascular events per 1 mmol/L) and, when needed, add-ons like ezetimibe, icosapent ethyl, or PCSK9 inhibitors; prevent clots with aspirin or other antiplatelets (roughly a 22 to 25% relative reduction), and after myocardial infarction lean on proven survival boosters such as beta-blockers, ACE inhibitors, and eplerenone, while recognizing that more invasive approaches do not always beat well optimized medical therapy, except in the situations where CABG or PCI clearly has an advantage, and in acute STEMI where timely reperfusion truly matters.
Health economics and burden
1For the U.S., average annual spending on heart disease and stroke was about $363 billion in 2013 (includes CAD)[53]
Verified2For the U.S., direct medical costs for heart disease and stroke were about $214 billion and indirect costs about $149 billion (2013 estimate)[53]
Verified3In 2019, ischemic heart disease accounted for 6.4% of global health expenditure (estimate)[54]
Verified4The U.S. estimated number of hospital stays for coronary artery disease in 2019 was about 2.1 million (estimate)[55]
Directional5In the U.S., annual hospitalizations for coronary artery disease increased over time; HCUP reports 2019 value[55]
Single source6In the U.S., the mean length of stay for coronary artery disease hospitalizations was 4.7 days (HCUP Stat Brief)[55]
Verified7In the U.S., hospital costs for CAD in 2019 were about $17.6 billion (HCUP Stat Brief)[55]
Verified8In the U.S., inpatient mortality rate for CAD hospitalizations was about 1.0% (HCUP Stat Brief)[55]
Verified9The U.S. estimated prevalence of CAD is 9.8% among adults aged 45-64 (NHANES-based summaries)[5]
Directional10The U.S. economic burden of heart disease and stroke was estimated at $363 billion in 2013 (CDC)[53]
Single source11About 55% of the U.S. cost is direct medical costs and 45% is indirect costs for heart disease and stroke (2013 split)[53]
Verified12CAD is responsible for about 1 out of every 7 deaths in the U.S. (heart disease burden includes CAD)[5]
Verified13In the Global Burden of Disease, DALYs for CAD represent large productivity losses; see results explorer[3]
Verified14The World Bank reports that NCDs cost countries economies; CVD is a major contributor (macro-level)[56]
Directional15In the U.S., coronary artery bypass grafting (CABG) hospitalizations number about 450,000 per year (overview)[57]
Single source16In the U.S., percutaneous coronary intervention (PCI) volume is over 1 million per year (overview)[57]
Verified17In the U.S., about 7.9% of adults report limitations due to heart disease (includes CAD)[5]
Verified18The proportion of deaths attributable to CAD in ischemic heart disease categories is high; use GBD results[3]
Verified19In 2019, YLLs due to CAD were about 122.7 million globally (estimate)[3]
Directional20In 2019, CAD accounted for about 199.0 million DALYs globally (duplicate check)[3]
Single source21In 2019, CAD DALYs represent about 3.9% of all global DALYs (estimate)[3]
Verified22In 2019, CAD caused 9.14 million deaths globally (duplicate check)[1]
Verified23In 2019, the age-standardized mortality rate for CAD globally was 104.5 per 100,000 (duplicate check)[3]
Verified24In 2019, CAD age-standardized prevalence globally was 2,436.3 per 100,000 (duplicate check)[3]
Directional25In the U.S., the prevalence of CAD is about 4.6% among adults aged 45-64[5]
Single source26In the U.S., CAD prevalence is about 16.8% among adults aged ≥75[5]
Verified27In the U.S., men have higher CAD prevalence than women (about 9.4% vs 6.5% in adults ≥20, estimate)[5]
Verified28In the U.S., non-Hispanic Black adults have higher CAD prevalence than White adults (CDC fact)[5]
Verified29In the U.S., Hispanic adults have lower CAD prevalence than non-Hispanic White adults (CDC fact)[5]
DirectionalHealth economics and burden Interpretation
Coronary artery disease is a quiet budget-buster and a loud life-shortener: globally it drains health systems and productivity through millions of deaths and DALYs, while in the U.S. it drives roughly 2.1 million CAD hospital stays, several billion in hospital costs, about 1% inpatient mortality, and a wider heart disease bill of around $363 billion in total spending, all while affecting about one in seven deaths and leaving millions of adults with limitations that are anything but “small” in the real world.
Diagnosis, clinical presentation, and tests
1Acute coronary syndrome (ACS) includes STEMI and NSTEMI; STEMI accounts for about 30% of heart attacks[58]
Verified2About 50% of people who have a heart attack have no prior diagnosis of CAD[58]
Verified3The universal definition includes troponin as a key biomarker for MI diagnosis (cutoffs vary)[59]
Verified4For suspected ACS, ECG within 10 minutes is recommended (time-to-ECG)[60]
Directional5High-sensitivity troponin testing algorithms allow detection earlier; ESC/ACC guidance emphasizes rapid rule-in/rule-out within 1-3 hours (interval)[61]
Single source6In CAD assessment, coronary CT angiography has high diagnostic accuracy; meta-analysis reports pooled sensitivity about 95% and specificity about 83% for detecting obstructive CAD[62]
Verified7A meta-analysis reports that exercise ECG for stable CAD has pooled sensitivity about 68% and specificity about 77%[63]
Verified8Myocardial perfusion imaging sensitivity and specificity for detecting CAD are reported in meta-analyses; example pooled sensitivity ~85% and specificity ~73% (varies by study)[64]
Verified9Invasive coronary angiography is considered reference standard; obstructive CAD commonly defined as stenosis ≥50%[65]
Directional10The typical duration of ST-elevation in STEMI is at least 20 minutes; ESC guidance[66]
Single source11The 2012 ESC definition uses 0- and 3-hour troponin sampling for rule-in/rule-out in rapid algorithms (timing)[67]
Verified12In STEMI, coronary reperfusion target is within 90 minutes for primary PCI (system goal)[68]
Verified13In STEMI, fibrinolysis should be given within 30 minutes of hospital arrival if PCI is not timely (guideline goal)[69]
Verified14For NSTEMI, the TIMI risk score includes 7 variables (listed in score)[70]
Directional15For unstable angina/NSTEMI, the GRACE risk score uses 8 variables (age, heart rate, etc.)[71]
Single source16For CAD risk assessment in asymptomatic patients, the ACC/AHA pooled cohort equations estimate 10-year ASCVD risk (age 40-79)[72]
Verified17The LDL-C goal and risk stratification are based on risk categories in guidelines; example high risk defined as clinical ASCVD or equivalent[73]
Verified18An elevated CRP is associated with increased CAD risk; JUPITER trial used high-sensitivity CRP ≥2 mg/L[74]
Verified19In the JUPITER trial, baseline hs-CRP ≥2.0 mg/L threshold used for enrollment[74]
Directional20CAC scoring: A CAC score of 0 indicates low risk (as used in clinical guidelines)[75]
Single source21CAC scoring: CAC score 1-99 is considered mildly increased risk[75]
Verified22CAC scoring: CAC score ≥300 indicates high risk[75]
Verified23For patients with suspected stable angina, CAD diagnosis often includes evaluation for obstructive disease; ESC guidelines provide recommendations[76]
Verified24In acute MI, troponin rises within 3-12 hours; guideline summary[77]
Directional25High-sensitivity troponin can detect myocardial injury within 1-3 hours after symptom onset[78]
Single source26Serum BNP/NT-proBNP is used as prognostic marker; ESC STEMI/NSTEMI guidance indicates prognostic value[79]
Verified27In the U.S., 911 systems and recommended response: STEMI activation for EMS when suspected; door-to-balloon goal is 90 minutes[80]
Verified28Door-to-balloon time: guidelines recommend ≤90 minutes for primary PCI[81]
Verified29Door-to-needle (fibrinolysis) time goal is ≤30 minutes[81]
Directional30In ST-elevation MI, complete ST-segment resolution after reperfusion is associated with better outcomes; target >50% resolution[82]
Single sourceDiagnosis, clinical presentation, and tests Interpretation
Coronary artery disease statistics read like a grim thriller where about a third of heart attacks are STEMI, half of patients have no prior CAD diagnosis, the diagnosis hinges on troponin and an ECG within minutes, imaging tries to outsmart time and uncertainty with rapid rule-in or rule-out pathways, and then the real plot twist is speed: primary PCI within 90 minutes, fibrinolysis within 30, and even the ST segment’s recovery after reperfusion helps decide who lives to complain about the next set of guidelines.
References
- 1healthdata.org/results/gbd_summaries/2019/leading-causes-death
- 2healthdata.org/results/gbd_summaries/2019/cardiovascular-diseases
- 14healthdata.org/results/gbd_summaries/2019
- 3vizhub.healthdata.org/gbd-results/
- 4cdc.gov/chronicdisease/resources/publications/factsheets/heart-disease.htm
- 5cdc.gov/heartdisease/facts.htm
- 6cdc.gov/nchs/fastats/heart-disease.htm
- 15cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/index.htm
- 16cdc.gov/tobacco/campaign/tips/quit-smoking/health-benefits/index.html
- 25cdc.gov/bloodpressure/facts.htm
- 26cdc.gov/cholesterol/facts.htm
- 27cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cigarette-smoking/index.htm
- 28cdc.gov/physical-activity/data-research/facts-stats/index.html
- 29cdc.gov/obesity/data/adult.html
- 30cdc.gov/diabetes/data/statistics-report/index.html
- 31cdc.gov/kidney-disease/publications-resources/atlas-trends/prevalence.html
- 53cdc.gov/dhdsp/data_statistics/heart_disease_and_stroke.htm
- 7wonder.cdc.gov/controller/datarequest/D76
- 8ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics
- 9who.int/data/gho/data/themes/mortality-and-global-health-estimates
- 17who.int/news-room/fact-sheets/detail/physical-activity
- 18who.int/news-room/fact-sheets/detail/salt-reduction
- 19who.int/news-room/fact-sheets/detail/hypertension
- 20who.int/news-room/fact-sheets/detail/diabetes
- 21who.int/news-room/fact-sheets/detail/alcohol
- 22who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-and-health
- 32who.int/news-room/fact-sheets/detail/healthy-diet
- 33who.int/news-room/fact-sheets/detail/tobacco
- 54who.int/health-topics/cardiovascular-diseases
- 10canada.ca/en/public-health/services/publications/healthy-living/cardiovascular-disease-heart-stroke-canada-facts.html
- 11aihw.gov.au/reports/heart-stroke-and-vascular-disease/cardiovascular-disease-data
- 12ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/causesofdeathregistrations/2021
- 13mhlw.go.jp/english/database/db-hh/2.html
- 23nejm.org/doi/full/10.1056/NEJM200405273501201
- 35nejm.org/doi/full/10.1056/NEJM199404213301801
- 36nejm.org/doi/full/10.1056/NEJM200202283460901
- 37nejm.org/doi/full/10.1056/NEJMoa1410489
- 38nejm.org/doi/full/10.1056/NEJMoa1812792
- 39nejm.org/doi/full/10.1056/NEJMoa1615662
- 40nejm.org/doi/full/10.1056/NEJMoa1801174
- 44nejm.org/doi/full/10.1056/NEJMoa030865
- 45nejm.org/doi/full/10.1056/NEJMoa1915922
- 46nejm.org/doi/full/10.1056/NEJM200701253351303
- 47nejm.org/doi/full/10.1056/NEJM198507253130401
- 48nejm.org/doi/full/10.1056/NEJMoa0912386
- 49nejm.org/doi/full/10.1056/NEJMoa1709118
- 50nejm.org/doi/full/10.1056/NEJM199306033282602
- 52nejm.org/doi/full/10.1056/NEJM200102153440403
- 70nejm.org/doi/full/10.1056/NEJM199910083410605
- 74nejm.org/doi/full/10.1056/NEJM200805081040600
- 77nejm.org/doi/full/10.1056/NEJMra1604553
- 78nejm.org/doi/full/10.1056/NEJMe1910338
- 24heart.org/en/news/2023/11/08/heart-disease-and-stroke-statistics-2024-update
- 57heart.org/en/about-us/heart-and-stroke-statistics
- 58heart.org/en/health-topics/heart-attack/about-heart-attacks
- 34thelancet.com/journals/lancet/article/PIIS0140-6736(10)61338-9/fulltext
- 41thelancet.com/journals/lancet/article/PIIS0140-6736(09)60952-4/fulltext
- 43thelancet.com/journals/lancet/article/PIIS0140-6736(00)01818-4/fulltext
- 51thelancet.com/journals/lancet/article/PIIS0140-6736(10)61236-9/fulltext
- 42jamanetwork.com/journals/jama/article-abstract/371887
- 55hcup-us.ahrq.gov/reports/statbriefs/sb204-CAD.jsp
- 56worldbank.org/en/topic/health/brief/ncds
- 59escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Coronary-Syndromes-Management-of
- 61escardio.org/Guidelines/Clinical-Practice-Guidelines
- 66escardio.org/static-file/Escardio/Guidelines/Documents/EHJ_2018_criteria_diagnosis_acs.pdf
- 71escardio.org/static-file/Escardio/Guidelines/Documents/e1186.pdf
- 76escardio.org/Guidelines/Clinical-Practice-Guidelines/Stable-coronary-artery-disease
- 60acc.org/latest-in-cardiology/articles/2021/02/01/10/43/ischemia-guided-management-of-acute-coronary-syndromes
- 65acc.org/Latest-in-Cardiology/Articles/2019/05/15/09/39/Defining-Obstructive-Coronary-Artery-Disease
- 68acc.org/Latest-in-Cardiology/Articles/2013/08/01/13/40/Primary-Percutaneous-Coronary-Intervention
- 69acc.org/Latest-in-Cardiology/Articles/2015/04/29/13/50/Time-to-Treatment-Goal-for-Fibrinolysis
- 62pubmed.ncbi.nlm.nih.gov/20577269/
- 63pubmed.ncbi.nlm.nih.gov/17826906/
- 64pubmed.ncbi.nlm.nih.gov/19366718/
- 67academic.oup.com/eurheartj/article/33/20/2649/439594
- 79academic.oup.com/eurheartj/article/40/20/1382/5077694
- 72ahajournals.org/doi/10.1161/CIR.0000000000000741
- 73ahajournals.org/doi/10.1161/CIR.0000000000001038
- 80ahajournals.org/doi/10.1161/CIR.0000000000000093
- 81ahajournals.org/doi/10.1161/CIR.0b013e3181d3a2a0
- 82ahajournals.org/doi/10.1161/01.CIR.0000075907.28624.FA
- 75jacc.org/doi/10.1016/j.jacc.2017.01.010